Hopp til innhold
NHI.no
Annonse

Tardive dyskinesier: Årsak

Innhold i artikkelen

Tardive dyskinesier opptrer oftest blant pasienter med schizofreni, manisk-depressive lidelser og andre psykiatriske tilstander som krever langvarig behandling med antipsykotika, men tilstanden kan av og til opptre også hos andre pasienter.

Annonse

Det er særlig de ufrivillige bevegelsene i ansikt og munn som er iøynefallende. Men det kan også oppstå Parkinsonliknende tilstander (se Parkinsons sykdom) preget av langsomme bevegelser, stivhet og pilletrille-skjelving. Disse bevegelsesforstyrrelsene som skyldes bruk av dopaminantagonister kalles med et annet fellesnavn for ekstrapyramidale bivirkninger.

Dette dokumentet er basert på det profesjonelle dokumentet Medikamentind. motoriske forstyr . Referanselisten for dette dokumentet vises nedenfor

  1. Buckley N, Mc Manus P. Fatal toxicity of drugs used in treatment of psychotic illnesses. Br J Psychiatry 1998: 172; 461-4
  2. Lima AR, Soares-Weiser K, Bacalthchuk J, Barnes TRE. Benzodiazepines for neuroleptic-induced acute akathisia (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software. The Cochrane Library
  3. Citrome L. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract. 2017. PMID: 29024264 PubMed
  4. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD000459. DOI: 10.1002/14651858.CD000459.pub2. DOI
  5. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD000209. DOI: 10.1002/14651858.CD000209.pub2. DOI
  6. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2015; 4: CD010501. pmid:25866243 PubMed
  7. Tammenmaa I, McGrath J, Sailas EES, Soares-Weiser K. Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No.: CD000207. DOI: 10.1002/14651858.CD000207. DOI
  8. Soares KVS, McGrath JJ. Anticholinergic medication for neuroleptic-induced tardive dyskinesia (Cochrane Review). In: The Cochrane Library, Issue 4, 2000. Oxford: Update Software. The Cochrane Library
  9. Alabed S, Latifeh Y, Mohammad HA, Rifai A. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD000203. DOI: 10.1002/14651858.CD000203.pub3. DOI
  10. Essali A, Deirawan H, Soares-Weiser K, Adams CE. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD000206. DOI: 10.1002/14651858.CD000206.pub3. DOI
  11. Soares-Weiser K, Irving CB, Rathbone J. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD000208. DOI: 10.1002/14651858.CD000208. DOI
  12. Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 20;1:CD000205. doi: 10.1002/14651858.CD000205.pub3. (Review) PMID: 29352477 PubMed
Annonse
Annonse